SAN DIEGO, Dec. 8, 2015 /PRNewswire/ -- Ansun BioPharma announced preliminary data suggesting in-vitro activity of DAS181 against Respiratory Syncytial Virus (RSV), a virus which causes significant morbidity and mortality in patients. The data was presented at the 5th Congress of Virology in Atlanta, Georgia in a keynote address by Ronald Moss, MD, CEO of Ansun. The in-vitro inhibition against the virus was observed to be more potent than Ribavarin, the current treatment for RSV. "This is very important data as RSV is a common respiratory pathogen and additional treatments are needed," noted Dr. Moss. "As DAS181 is currently in the clinic being studied for the treatment of other respiratory viruses, clinical trials are warranted to test the efficacy of this drug against RSV infection as well," commented Dr. Moss.
About Ansun BioPharma
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. DAS181 has two indications in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of severe parainfluenza infection in immunocompromised patients. ParaDaseTM has received Fast Track Designation by the U.S. FDA. Preclinical data suggests that DAS181 may have additional activity against other respiratory viruses. For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.
SOURCE Ansun BioPharma